Introducing the most comprehensive commercially available NGS assay for detecting gene fusions in cancer using an automated nanoscale library prep workflow SOUTH SAN FRANCISCO, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider
The first commercially available targeted NGS assay that enables simultaneous detection of somatic variants across 53 solid tumor genes using a highly efficient microfluidic library prep workflow SOUTH SAN FRANCISCO, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an
SOUTH SAN FRANCISCO, Calif. , May 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of May 7, 2019 , under Fluidigm’s 2017
SOUTH SAN FRANCISCO, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in two upcoming investor
First quarter revenue increased 19 percent to $30.1 million Mass cytometry revenue growth of 110 percent in first quarter Strong mass cytometry and Imaging Mass Cytometry instrument adoption First complete sample-to-answer solution for deep immune profiling in mass cytometry SOUTH SAN FRANCISCO,
SOUTH SAN FRANCISCO, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) announced today that the Group for Innovative Cancer Treatment Division of the National Cancer Center in Japan has expanded its clinical research in colorectal cancer using the Hyperion™ Imaging
Fluidigm invites researchers to the world’s largest global mass cytometry conference in Vancouver, Canada SOUTH SAN FRANCISCO, Calif. , April 30, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
SOUTH SAN FRANCISCO, Calif. , April 04, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report first quarter 2019 financial results on Thursday,
A comprehensive suite of multi-omic cancer research solutions for deep profiling of the tumor microenvironment and immune response SOUTH SAN FRANCISCO, Calif. , March 28, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve
The new standard in immune profiling for advancing translational and clinical research of immune-mediated diseases SOUTH SAN FRANCISCO, Calif. , March 28, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
